SCHEDULE 13D/A: Fresenius Medical Care's Stake in Humacyte Diluted to 11.8% Following Increased Share Count
Beneficial Ownership Amendment
Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG reported a decrease in their beneficial ownership of Humacyte, Inc. common stock from 14.2% to 11.8%, solely due to an increase in Humacyte's outstanding shares.
Summary
- Fresenius Medical Care Holdings, Inc. (FMCH) and Fresenius Medical Care AG (FME AG) filed Amendment No. 4 to their Schedule 13D regarding their beneficial ownership in Humacyte, Inc.
- As of May 13, 2025, FMCH beneficially owns 18,312,735 shares of Humacyte's Common Stock.
- This represents approximately 11.8% of Humacyte's outstanding voting shares, calculated based on 155,118,816 shares outstanding as of May 5, 2025, as reported by Humacyte in its Form 10-Q.
- The percentage beneficial ownership for the Filing Persons has decreased from 14.2% (as reported in Amendment No. 3) to 11.8%.
- This decrease is solely attributed to an increase in the total number of outstanding shares of Humacyte's Common Stock since the filing of Amendment No. 3.
- Neither FMCH nor FME AG has acquired or disposed of any shares of Humacyte's Common Stock since their initial Schedule 13D filing in September 2021.
- Fresenius SE is reported as the beneficial owner of 83,780,382 shares of FME AG, constituting 28.6% of FME AG's outstanding shares, as of March 10, 2025.
Sentiment
Score: 5
Explanation: The document is a factual update on beneficial ownership percentage due to share dilution, with no explicit positive or negative operational news from the company itself. The sentiment is neutral as it reports a mathematical consequence of a previously reported event (increased share count).
Negatives
- The decrease in Fresenius Medical Care's percentage ownership from 14.2% to 11.8% indicates dilution for existing shareholders of Humacyte, Inc. due to an increase in the total number of outstanding shares.
Future Outlook
The document does not provide any forward-looking statements or guidance.
Industry Context
This filing is a routine disclosure of a change in beneficial ownership percentage for a significant shareholder in a publicly traded biotechnology company. The dilution of ownership percentage is a common occurrence in industries where companies frequently raise capital or issue shares for various strategic purposes.
Stakeholder Impact
- Shareholders: The increase in outstanding shares, which led to the dilution of Fresenius Medical Care's stake, implies a dilution of ownership for all existing shareholders unless they participated proportionally in the share issuance.
Key Dates
| Date | Description |
|---|---|
| 2021-09-02 | Original Schedule 13D filing date by Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG. |
| 2023-12-01 | Filing date of Amendment No. 1 to the Schedule 13D. |
| 2024-03-07 | Filing date of Amendment No. 2 to the Schedule 13D. |
| 2024-11-18 | Filing date of Amendment No. 3 to the Schedule 13D. |
| 2025-03-10 | Date of Schedule 13D (Amendment No. 11) filed by Fresenius SE, reporting its beneficial ownership in FME AG. |
| 2025-05-05 | Date as of which Humacyte, Inc. reported 155,118,816 shares outstanding in its quarterly report on Form 10-Q. |
| 2025-05-13 | Date of event which requires the filing of this Amendment No. 4 to the Schedule 13D. |
| 2025-05-22 | Signature date for Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG on the Schedule 13D Amendment No. 4. |
Keywords
Humacyte Inc., Fresenius Medical Care, Schedule 13D, Beneficial Ownership, Share Dilution, Common Stock, SEC Filing, Corporate Governance, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.